The aim of this study is to evaluate the relationship between the pharmacokinetic (PK) endpoints (i.e., AUC) and clinical effects or the occurrence of nephrotoxicity by performing therapeutic drug monitoring (TDM) in Korean patients with MRSA infection.
-Subjects registered before the initiation of vancomycin administration should perform baseline examinations within 2 weeks prior to vancomycin administration. In the case of subjects registered after the initiation of dosing, baseline information can be collected retrospectively, or baseline tests can be conducted within 3 days after the initiation of dosing.
-On day 1(before vancomycin administration) and days 2-7 after the initiation of vancomycin administration, urine collection will be performed for biomarker exploration.
-On days 3, 7, and 10, blood samples will be collected For PK evaluation at 1.5 h (between 1-2 h) after the end of intravenous administration and 30 minutes before the next dose (trough level) with clinical laboratory tests (creatinine, cystatin C). Blood collection for TDM will be performed approximately twice per patient and may vary depending on the dosing schedule and renal function. 
-In this study, blood samples collected in the Biobank of Kangwon National University Hospital will be used for genotype analysis.

Cohort/Group Label

Korean patients who are expected to receive vancomycin for 7 days or more for the treatment of MRSA infection, or within 3 days after initiation of vancomycin administration

Cohort/Group Description

These study procedures will be conducted in Korean patients who are expected to receive vancomycin for 7 days or more for the treatment of MRSA infection, or within 3 days after initiation of vancomycin administration.
1. The baseline tests (demographic information collection, clinical laboratory tests, exploratory biomarker tests, etc.) are conducted to the enrolled patients within 2 weeks before initiation of the vancomycin dosing. 
2. On day 1(before vancomycin administration) and days 2-7 after the initiation of vancomycin administration, urine collection will be performed for biomarker exploration. 
3. On days 3, 7, and 10, blood samples will be collected for PK evaluation at 1.5 h (between 1-2 h) after the end of intravenous administration and 30 minutes before the next dose (trough level) with clinical laboratory tests (creatinine, cystatin C). Blood collection for TDM will be performed approximately twice per patient and may vary depending on the dosing schedule and renal function. 
4. In this study, blood samples collected in the Biobank of Kangwon National University Hospital will be used for genotype analysis.

: DNA Collect & Archive: Sample without DNA

Urine

Men and women over 19 years of age who were decided to administer vancomycin due to MRSA infection at Kangwon National University Hospital

Non-probablity sampling: All men and women over 19 years of age who were decided to administer vancomycin due to MRSA infection at Kangwon National University Hospital and selected for this study will be enrolled.

Gender

Age

Description

① Patients who have the ability to sign the consent form in accordance with GCP and corresponding laws
② Patients who are 19 years or older
③ Patients who were decided to administer vancomycin for 7 days or more due to MRSA infection or within 3 days after initiation of vancomycin dosing
④ Patient who understands the contents of the clinical research and provide their written informed consent forms

① Patients who co-administered vancomycin, except for the intravenous route. (e.g., per oral)
② Patients with contraindications for vancomycin (e.g., Anaphylaxis due to vancomycin) 
③ Patients in pregnancy or lactation 
④ Patients whom the researcher deemed inappropriate for clinical research participation

Pharmacokinetic parameters (AUC, Ctrough)

Day 3, Day 7, and Day 10 after initiation of vancomycin dosing

Occurrence of nephrotoxicity

Prior to vancomycin dosing(Day 1) and Days 2-7 after initiation of vancomycin dosing